The combination of Tranilast and Doxil also significantly increased the levels of immunostimulatory M1 macrophages in tumor tissue, enhancing the efficacy of immune checkpoint inhibitors (such as anti-PD-1/anti-CTLA-4) (Panagi et al., 2020). This evidence concerns the gene CTLA4 and neoplasm.